SG11202011461TA - Anti-pvrig/anti-tigit bispecific antibodies and methods of use - Google Patents

Anti-pvrig/anti-tigit bispecific antibodies and methods of use

Info

Publication number
SG11202011461TA
SG11202011461TA SG11202011461TA SG11202011461TA SG11202011461TA SG 11202011461T A SG11202011461T A SG 11202011461TA SG 11202011461T A SG11202011461T A SG 11202011461TA SG 11202011461T A SG11202011461T A SG 11202011461TA SG 11202011461T A SG11202011461T A SG 11202011461TA
Authority
SG
Singapore
Prior art keywords
pvrig
methods
bispecific antibodies
tigit bispecific
tigit
Prior art date
Application number
SG11202011461TA
Other languages
English (en)
Inventor
Andrew Drake
Sandeep Kumar
Sayantan Mitra
Adam Salles
Sarah Whelan
Arun Kashyap
Keith Akama
Neha Yevalekar
Carlos Fabricio Santamaria
Original Assignee
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen Ltd filed Critical Compugen Ltd
Publication of SG11202011461TA publication Critical patent/SG11202011461TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202011461TA 2018-06-01 2019-05-31 Anti-pvrig/anti-tigit bispecific antibodies and methods of use SG11202011461TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679703P 2018-06-01 2018-06-01
US201862773586P 2018-11-30 2018-11-30
PCT/US2019/035062 WO2019232484A1 (en) 2018-06-01 2019-05-31 Anti-pvrig/anti-tigit bispecific antibodies and methods of use

Publications (1)

Publication Number Publication Date
SG11202011461TA true SG11202011461TA (en) 2020-12-30

Family

ID=67003669

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011461TA SG11202011461TA (en) 2018-06-01 2019-05-31 Anti-pvrig/anti-tigit bispecific antibodies and methods of use

Country Status (14)

Country Link
US (1) US20190382477A1 (zh)
EP (1) EP3802605A1 (zh)
JP (1) JP2021525087A (zh)
KR (1) KR20210016448A (zh)
CN (1) CN113039202A (zh)
AU (1) AU2019276578A1 (zh)
BR (1) BR112020024249A2 (zh)
CA (1) CA3101019A1 (zh)
CL (1) CL2020003127A1 (zh)
CO (1) CO2020016619A2 (zh)
IL (1) IL279053A (zh)
MX (1) MX2020012797A (zh)
SG (1) SG11202011461TA (zh)
WO (1) WO2019232484A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
KR20220154140A (ko) 2020-03-13 2022-11-21 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pvrig 결합 단백질 및 이의 의학적 용도
CA3176497A1 (en) 2020-05-07 2021-11-11 Fatima MECHTA-GRIGORIOU Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
US20210395366A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
WO2022165266A1 (en) * 2021-01-28 2022-08-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
WO2022165275A2 (en) * 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
AU2022219332A1 (en) * 2021-02-09 2023-09-21 Shanghai Junshi Biosciences Co., Ltd. Anti-cd112r antibody and use thereof
AU2022219681A1 (en) 2021-02-11 2023-09-21 Nectin Therapeutics Ltd. Antibodies against cd112r and uses thereof
IL307419A (en) 2021-04-09 2023-12-01 Ose Immunotherapeutics A new scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CN115010800A (zh) * 2021-06-10 2022-09-06 百奥赛图(北京)医药科技股份有限公司 Pvrig基因人源化非人动物的构建方法及应用
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
AU2022320667A1 (en) * 2021-07-30 2024-03-14 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibody and application
TW202317644A (zh) * 2021-09-15 2023-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種含抗ｐｖｒｉｇ／ｔｉｇｉｔ雙特異性抗體的醫藥組成物
CN117940453A (zh) * 2021-09-15 2024-04-26 江苏恒瑞医药股份有限公司 特异性结合pd-1的蛋白及其医药用途
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN114057867B (zh) * 2021-12-14 2023-05-12 河南联科物联网科技有限公司 一种抗减蛋综合征的单克隆抗体及其应用
CN116925222A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pvrig抗体、其药物组合物及用途
CN116925233A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
TW202402325A (zh) * 2022-06-08 2024-01-16 大陸商山東先聲生物製藥有限公司 Pvrig/tigit雙特異性抗體藥物組合物及其用途
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
JP4889505B2 (ja) 2004-02-02 2012-03-07 アンブレツクス・インコーポレイテツド 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011131746A2 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CA2812739A1 (en) 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
CN114163530A (zh) 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
KR20150018604A (ko) * 2012-06-06 2015-02-23 온코메드 파마슈티칼스, 인크. 히포 경로를 조절하는 결합제 및 그의 용도
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
EP2951203B1 (en) 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
PT3021869T (pt) 2013-07-16 2020-09-10 Hoffmann La Roche Métodos de tratamento do cancro com antagonistas da ligação ao eixo pd-1 e inibidores do tigit
AP2016009475A0 (en) 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
MX2017002229A (es) 2014-08-19 2017-05-09 Merck Sharp & Dohme Anticuerpos anti tigit.
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
JP7115856B2 (ja) 2015-02-19 2022-08-09 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体及び使用方法
AU2016315892B2 (en) 2015-09-02 2023-06-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
UA125062C2 (uk) 2015-10-01 2022-01-05 Потенза Терапеутікс, Інк. Анти-tigit антигензв'язуючі білки і способи їх застосування
IL261188B (en) 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
RU2767357C2 (ru) 2016-06-14 2022-03-17 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
CN110088132B (zh) * 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3630180A1 (en) * 2017-06-01 2020-04-08 Compugen Ltd. Triple combination antibody therapies

Also Published As

Publication number Publication date
BR112020024249A2 (pt) 2021-03-02
CL2020003127A1 (es) 2021-10-29
IL279053A (en) 2021-01-31
MX2020012797A (es) 2021-03-25
CN113039202A (zh) 2021-06-25
WO2019232484A9 (en) 2021-05-06
EP3802605A1 (en) 2021-04-14
JP2021525087A (ja) 2021-09-24
US20190382477A1 (en) 2019-12-19
AU2019276578A1 (en) 2021-01-14
WO2019232484A1 (en) 2019-12-05
CA3101019A1 (en) 2019-12-05
KR20210016448A (ko) 2021-02-15
CO2020016619A2 (es) 2021-01-18

Similar Documents

Publication Publication Date Title
IL279053A (en) Bispecific anti-PVRIG/ anti-TIGIT antibodies and methods of use
IL276731A (en) Antibodies against CD73 and methods of using them
IL278821A (en) Anti-SIRPA antibodies and methods of using them
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
HUE062927T2 (hu) Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
HUE062436T2 (hu) Anti-trem2 antitestek és alkalmazási módszereik
IL278772A (en) Antibodies against 40-OX and methods of use
IL270214A (en) Anti-sortilin antibodies and methods of using them
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL287282A (en) Anti-mertk antibodies and methods of using them
SG11202106498XA (en) Anti-ctla4 antibodies and methods of use thereof
IL290741A (en) Antibodies against cd-96 and methods of using them
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL285401A (en) Anti-clec2d antibodies and methods of using them
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL271346A (en) Bispecific antibodies and methods for their preparation and use
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them
EP4061848A4 (en) ANTI-ROR-2 ANTIBODIES AND METHODS OF USE
EP3994174A4 (en) MONOSPECIFIC ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE
IL273538A (en) Anti-TRKB Monoclonal Antibodies and Methods of Use
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same